Annovis Completes Enrollment in Pivotal Alzheimer's Trial, Data Readouts Set for 2027
ANVS sits 29% above its 52-week low of $1.541.
Summary
Annovis Bio has fully enrolled its Phase 3 trial of buntanetap in early Alzheimer's disease, reaching the target of 850 patients across 83 U.S. sites. This is a critical milestone for the company, which has been navigating a precarious cash position and recent dilutive financings. The trial's dual readout design—6-month symptomatic data in Q1 2027 and 18-month disease-modifying data in Q1 2028—provides two near-term catalysts that could significantly de-risk the asset. With separate NDA submissions planned after each readout, the company is positioning for a potential accelerated path to market. The enrollment completion follows the $15 million offering in May that extended the cash runway, but the company will likely need additional capital before the first data readout.
At the time of this announcement, ANVS was trading at $1.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $83M. The 52-week trading range was $1.54 to $5.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.